• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Quadrivalent recombinant influenza vaccine noninferior to inactivated vaccine

byMatthew Lin, MDandLeah Carr, MD
April 2, 2018
in Infectious Disease, Pediatrics, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The quadrivalent recombinant influenza vaccine (RIV4) was noninferior when compared with the quadrivalent inactivated influenza vaccine (IIV4) for immunogenicity.

Evidence Rating Level: 1 (Excellent)

Study Rundown:  Seasonal influenza vaccines have recently been transitioned to a quadrivalent, recombinant formulation to provide broadened protection against 2 antigenically distinct influenza type B lineages in addition to the conventional type A subtypes. In adults, the RIV4 has shown greater efficacy in protecting against laboratory-confirmed influenza-like illness compared to the IIV4. While recombinant vaccines contain a portion of DNA encoding for a viral antigen, an inactivated vaccine contains a killed virus. Additionally, recombinant vaccines circumvent the need for egg-based incubation and therefore take less time to produce and do not contain genetic mutations that may reduce effectiveness.1 In this phase 2 randomized controlled study, researchers evaluated the immunogenicity and safety profile of the RIV4 compared to the IIV4 in pediatric patients 6-17 years of age. In light of prior trial data, this age range was selected based on the hypothesis that immunogenic responses may be stronger in children who have already been primed by previous vaccinations or infections. The RIV4 satisfied noninferiority criteria for all 4 antigenic lineages based on HAI GMTs, and satisfied noninferiority criteria for all antigenic lineages based on HAI SCRs with the exception of the Influenza-B Victoria Lineage. The safety profile was comparable between both vaccination groups. Within 7 days following the injection, the most common reactions included pain at the injection site, myalgias, and headache. Limitations included a smaller sample size for the younger cohort, resulting in wider confidence intervals. This study has shown that the RIV4 is comparable to IIV4 in terms of safety and immunogenicity in pediatric patients, but further trial data is needed to assess efficacy.

Click to read the study published today in Pediatrics

Relevant Reading: The rationale for the quadrivalent influenza vaccines

In-Depth [randomized controlled trial]: This phase 2 randomized controlled trial included a total of 219 subjects and was conducted at 5 outpatient research centers. An older cohort (N=159) of subjects 9-17 years of age was initially enrolled between November 2013 to December 2013 and once safety data from this cohort had been reviewed, a younger cohort (N=60) of subjects 6-8 years of age between were enrolled during December 2013 to January 2014. Subjects were excluded if they had serious underlying medical conditions, acute febrile illness, contraindications to study vaccines and/or were on immunosuppressive therapies. Subjects received either the RIV4 or IIV4, with the younger cohort receiving 2 doses a month apart. Immunogenicity was assessed with HAI antibody GMTs and SCRs at 28 days after vaccination completion, and an additional 56-day point for the younger cohort. Noninferiority was satisfied if the ratio between the upper limit of the confidence intervals for the GMTs of the IIV4 and RIV4 was ≤1.5. The RIV4 showed noninferiority immunogenicity for GMT ratios of all 4 antigenic lineages covered, but for SCRs, showed noninferiority for all lineages except the Influenza B-Victoria Lineage. For the younger cohort that received 2 doses of vaccination, antibody responses to the first dose were comparable to those after the second dose. The safety profiles of RIV4 and IIV4 were similar, with the most common side effect being pain secondary to injection. Other side effects during the first 7 days following injection included myalgia, fatigue and headache – during this time, fevers occurred in <5% of participants and none were >102F. In terms of serious adverse events, no deaths were reported. Out of 219 subjects, 203 (92.6%) completed the 6-month follow-up for evaluation of further vaccine-related adverse events, of which there were none reported.

Reference:
1 Dunkle LM, Izikson R, Patriarca P, Goldenthal KL et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med. 2017; 376: 2427-2436.

RELATED REPORTS

Single-dose baloxavir linked to reduced influenza transmission

#VisualAbstract: Baloxavir Treatment is Effective in Preventing Transmission of Influenza

The 2 Minute Medicine Podcast Episode 54

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: influenzavaccination
Previous Post

Venetoclax plus rituximab increases progression-free survival in relapsed chronic lymphocytic leukemia

Next Post

2 Minute Medicine Rewind April 2, 2018

RelatedReports

Influenza vaccine associated with lower risk of major cardiovascular events
Infectious Disease

Single-dose baloxavir linked to reduced influenza transmission

May 20, 2025
#VisualAbstract: Baloxavir Treatment is Effective in Preventing Transmission of Influenza
StudyGraphics

#VisualAbstract: Baloxavir Treatment is Effective in Preventing Transmission of Influenza

May 5, 2025
The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 54

March 21, 2025
Influenza vaccine not associated with increased risk of epilepsy in children
Infectious Disease

Influenza vaccination may reduce secondary infection spread amongst household contacts

December 1, 2024
Next Post

2 Minute Medicine Rewind April 2, 2018

Pathway modification reduces admissions for pediatric anaphylaxis

Pathway modification reduces admissions for pediatric anaphylaxis

All-cause mortality is increased for older adults with sudden loss of wealth in the US

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravenous hydrocortisone may reduce risk of kidney failure in patients with sepsis
  • Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension
  • Oral semaglutide reduces cardiovascular event rates in high-risk patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.